Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin

Abstract

Get full access to this article

View all access options for this article.

References

Farrell

. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance? J Clin Gastroenterol. 2013;47:205-211.

Liu

Bayer

Cosgrove

. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:1-38.

Xifaxan [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; 2015.

Valentin

Leitner

Rohn

. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34-38.

Valentin

Hoenigl

Wagner

Krause

Zollner-Schwetz

. Bacteraemia with rifampin-resistant Staphylococcus aureus and the potential role of cross-resistance between rifampin and rifaximin. J Infect. 2014;69:295-297.

Hoffman

Hartig

Sonbol

Lang

. Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother. 2011;45:e25.